Welcome to our dedicated page for UpStream Bio SEC filings (Ticker: UPB), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Trying to track dose-response data, cash runway and insider sentiment in Upstream Bio’s technical filings can feel like reading immunology textbooks. Each 10-K details multi-arm clinical trials, while 8-Ks announce pivotal safety updates that move the stock overnight. If you’ve searched for “Upstream Bio SEC filings explained simply,” this page is your shortcut.
Stock Titan’s AI breaks down every document the moment it posts to EDGAR. Open an Upstream Bio quarterly earnings report 10-Q filing and our platform highlights R&D spend trends. Click an 8-K and see “Upstream Bio 8-K material events explained” in plain language—no medical jargon required. Real-time alerts flag Upstream Bio insider trading Form 4 transactions, while the dashboard also lists “Upstream Bio executive stock transactions Form 4” so you can gauge management confidence. Need the big picture? Our summaries turn the 200-page “Upstream Bio annual report 10-K simplified” into key risks, cash position and pipeline timelines in minutes.
Whether you’re comparing trial endpoints or monitoring dilution risk, you’ll find every form here: 10-K, 10-Q, S-1, 13D, plus proxy statements that cover “Upstream Bio proxy statement executive compensation.” Analysts rely on our “Upstream Bio earnings report filing analysis” to model cash burn, while traders appreciate “Upstream Bio Form 4 insider transactions real-time” alerts before the market reacts. Stop scanning dense PDFs—start understanding Upstream Bio SEC documents with AI and make faster, better-informed decisions.
Upstream Bio (UPB) filed its Q3 2025 10‑Q, reporting higher R&D spend as it advances verekitug across three Phase 2 programs. Collaboration revenue was $683 thousand, while research and development expense rose to $32.975 million and general and administrative expense was $5.542 million, leading to a net loss of $33.748 million for the quarter.
For the nine months, the company recorded a net loss of $100.984 million as it scaled clinical activities. Cash, cash equivalents and short‑term investments were $372.4 million as of September 30, 2025, and management notes this liquidity is expected to fund operations through 2027. Operating cash use was $102.644 million year‑to‑date. The company reported positive top‑line results in CRSwNP in September 2025, completed enrollment in its severe asthma Phase 2 in June 2025 with top‑line data expected in the first quarter of 2026, and initiated a Phase 2 COPD trial in July 2025.
Upstream Bio, Inc. furnished an update on operations by announcing its results and business highlights for the quarter ended September 30, 2025. The company submitted a Form 8-K noting that a detailed press release was provided as Exhibit 99.1.
The information under Item 2.02, including Exhibit 99.1, is being furnished and is not deemed filed under the Exchange Act. Upstream Bio’s common stock trades on the Nasdaq Global Select Market under the symbol UPB.
Upstream Bio (UPB) Q2 2025 10-Q highlights. The clinical-stage biotech recorded collaboration revenue of $0.94 m (+84% YoY), while R&D expense jumped 169 % to $37.9 m as Phase 2 programs for verekitug in severe asthma, CRSwNP and COPD advanced. Total operating costs rose to $45.3 m, pushing the quarterly net loss to $40.0 m (-173 % YoY) or $(0.74) per share.
Despite the widening loss, liquidity remains robust: cash, cash equivalents and short-term investments total $393.6 m against only $11.8 m of liabilities. Operating cash burn was $80.4 m for the first half, but management believes existing resources fund operations “through 2027.” Interest income of $4.4 m partially offset expenses.
Pipeline momentum continues: CRSwNP Phase 2 enrollment completed Jan-25 with top-line data expected Q3-25; severe asthma Phase 2 enrollment finished Jun-25 with read-out due Q1-26; COPD Phase 2 began Jul-25. The filing reiterates typical biotech risks, notably single-asset dependence and future financing needs.
FAQ
What is the current stock price of UpStream Bio (UPB)?
What is the market cap of UpStream Bio (UPB)?
